Wayne Winegarden, PhD, discusses his savings analysis for adalimumab and etanercept biosimilars and their potential market share.
The Center for Biosimilars® interviewed Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation.
Winegarden talked about his analysis estimating savings for adalimumab and etanercept biosimilars under different market share scenarios. He said that in the long term, about 5 years after market introduction, a 75% market share for etanercept and adalimumab biosimilars should be doable and likely. It’s also possible at the 3-year mark after they enter the market. However, after 1 year on the market, he expects that biosimilar market share for either of these agents to be about 25% because it can take some time for people to adopt biosimilars.